ModelRefs / Clinical Evidence Synthesis — Architecture Blueprint

Clinical Evidence Synthesis — Architecture Blueprint

Production architecture blueprint for Clinical Evidence Synthesis: components, deployment patterns, cost & latency, failure modes, evaluation and governance, with sources and review dates.

Overview

This is the implementation view of Clinical Evidence Synthesis: the components it requires, where it can run, what it costs in latency and spend, how it fails, and what you must measure before putting it in front of users.

5 components to assemble, 6 documented failure modes, high implementation complexity. Every statement below comes from the canonical workflow record with its sources and review date; where the evidence does not settle a question, the page says so rather than filling the gap.

What this workflow takes in and produces

Takes in

  • declared search results
  • authorized full-text studies
  • study metadata
  • review protocol
  • extraction and appraisal rubric

Produces

  • candidate study inventories
  • source-linked evidence tables
  • uncertainty and disagreement flags
  • reviewer-ready synthesis drafts

Applied to

  • literature-screening support
  • source-linked evidence-table preparation
  • human-reviewed clinical evidence summaries

Components you need to assemble

A working implementation needs 5 distinct components. Each is a build-or-buy decision in its own right.

  • literature search and deduplication
  • document retrieval
  • citation and source-span capture
  • evidence-table schema
  • qualified clinical and methods review

Implementation complexity: high. This describes the integration and evaluation effort, not the difficulty of any single component.

Deployment patterns

Deployment options recorded for this workflow: managed-api, hybrid.

Topologies it has been recorded against: serverless-api, managed-container, hybrid-private-cloud. Each changes the data-residency, scaling and cost profile, so confirm the one you need against current provider documentation.

Cost and latency

  • Search retrieval, full-text access, duplicate resolution, specialist appraisal, and adjudication dominate cost and elapsed time.
  • Measure reviewer correction and missed-evidence risk rather than optimizing summary throughput alone.

How this workflow fails

Observed failure modes for this class of workflow. Design a check for each one before shipping, not after.

  • missed study
  • wrong inclusion decision
  • unsupported synthesis
  • citation mismatch
  • study-quality flattening
  • omitted disagreement or harm

Risk areas the evidence covers

  • search and screening recall
  • data-extraction accuracy
  • citation traceability
  • study-quality preservation
  • uncertainty and disagreement handling

Proving it works before you ship

Evaluation readiness: Partial — Screening, extraction, citation, omission, contradiction, appraisal, and reviewer-agreement measures are defined; review-question-specific gold cases and thresholds remain required.

Worked evaluation case: Expert-reviewed clinical evidence table and synthesis

Prepare a source-linked evidence table and synthesis draft from a protocol-defined study set while preserving study quality, disagreement, uncertainty, and omissions for expert review.

What to measure

  • study-screening recall and precision
  • field and outcome extraction accuracy
  • citation and source-span validity
  • study-quality and uncertainty preservation
  • reviewer correction, omission, and adjudication burden

Governance and data handling

  • Keep literature-only workflows separate from patient-context processing; apply approved privacy and security controls if patient information is introduced.
  • Require qualified clinical and methods review and preserve protocol deviations, exclusions, conflicts, and reviewer decisions.

Implementation notes

  • Version the review question, protocol, search strings, databases, dates, eligibility rules, study set, extraction schema, prompts, model, and reviewer decisions.
  • Preserve source page or span for every extracted result and explicitly represent missing, conflicting, heterogeneous, or low-quality evidence.

What this blueprint does not establish

  • Transparent reporting guidance does not establish that a search is complete or that a synthesis is clinically correct.
  • This workflow does not diagnose, recommend treatment, create guidelines, or replace systematic reviewers, clinicians, or methods experts.

Source coverage: Partial — PRISMA supports transparent reporting of identification, selection, appraisal, and synthesis; FDA CDS guidance supports reviewable bases for clinical recommendations. Neither validates an automated synthesis or clinical conclusion.

Sources reviewed 2026-07-02. Revalidate searches, publications, corrections, retractions, protocols, appraisal rules, model behavior, and reviewer policy for every update.

Sources

Candidate models and benchmarks

Candidate models with published references, the providers behind them, and the benchmarks whose task shape bears on this workflow are on the Clinical Evidence Synthesis workflow reference. This blueprint covers implementation; that page covers selection.

Continue your research

Use these connected ModelRefs sections to compare alternatives, inspect implementation paths, and review the evidence and governance boundaries relevant to Clinical Evidence Synthesis — Architecture Blueprint.